TABLE 2.
Prevalences of HPV genotypes by age in the screening population as assessed by the Onclarity assay
| HPV type | No. (%) positivea
in the following age group (yr): |
No. (%) positive in the total population (n = 998) | ||
|---|---|---|---|---|
| 30–39 (n = 383) | 40–49 (n = 408) | 50–59 (n = 207) | ||
| All hrHPV types | 63 (16.4) | 31 (7.6) | 19 (9.2) | 113 (11.3) |
| HPV16 | 10 (2.6) | 5 (1.2) | 3 (1.4) | 18 (1.8) |
| HPV18 | 7 (1.8) | 4 (1.0) | 0 (0.0) | 11 (1.1) |
| HPV31 | 6 (1.6) | 5 (1.2) | 1 (0.5) | 12 (1.2) |
| HPV45 | 6 (1.6) | 3 (0.7) | 2 (1.0) | 11 (1.1) |
| HPV51 | 4 (1.0) | 2 (0.5) | 2 (1.0) | 8 (0.8) |
| HPV52 | 12 (3.1) | 1 (0.2) | 4 (1.9) | 17 (1.7) |
| HPV33/58 | 8 (2.1) | 4 (1.0) | 5 (2.4) | 17 (1.7) |
| HPV56/59/66 | 14 (3.7) | 6 (1.5) | 3 (1.4) | 23 (2.3) |
| HPV35/39/68 | 13 (3.4) | 7 (1.7) | 3 (1.4) | 23 (2.3) |
a
All infections observed were counted regardless of whether they were observed as single infections or multiple infections.